AU2001284261A1 - Vaccine against microbial pathogens - Google Patents

Vaccine against microbial pathogens

Info

Publication number
AU2001284261A1
AU2001284261A1 AU2001284261A AU8426101A AU2001284261A1 AU 2001284261 A1 AU2001284261 A1 AU 2001284261A1 AU 2001284261 A AU2001284261 A AU 2001284261A AU 8426101 A AU8426101 A AU 8426101A AU 2001284261 A1 AU2001284261 A1 AU 2001284261A1
Authority
AU
Australia
Prior art keywords
heat shock
vaccine
present
shock protein
repressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284261A
Inventor
Camilo Anthony Leo Selwyn Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Publication of AU2001284261A1 publication Critical patent/AU2001284261A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides a vaccine comprising a microbial pathogen, wherein the microbial pathogen is subjected to a stress inducing stimuli. The stress inducing stimuli can be heat or osmotic stress, through preferably the microbial pathogen is genetically modified such that at least one repressor gene for a heat shock protein gene is inactivated, thus allowing the constitutive expression of heat shock proteins. In particular the use of heat shock protein repressor mutant bacteria is shown to be effective for inducing immunity when comprised within vaccines of the present invention. The present invention further provides a method for producing a vaccine comprising stressed induced microbial pathogens and further the use of the heat shock protein repressor deletion mutant microbes as vaccine vectors which can be additionally allow the expression of heterologous antigen fragments.
AU2001284261A 2000-09-04 2001-09-04 Vaccine against microbial pathogens Abandoned AU2001284261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0021757.0 2000-09-04
GBGB0021757.0A GB0021757D0 (en) 2000-09-04 2000-09-04 Vaccine against microbial pathogens
PCT/GB2001/003964 WO2002020045A2 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Publications (1)

Publication Number Publication Date
AU2001284261A1 true AU2001284261A1 (en) 2002-03-22

Family

ID=9898866

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284261A Abandoned AU2001284261A1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Country Status (15)

Country Link
US (1) US20050232946A1 (en)
EP (1) EP1315518B1 (en)
JP (1) JP2004508339A (en)
CN (1) CN1452495A (en)
AT (1) ATE450270T1 (en)
AU (1) AU2001284261A1 (en)
CA (1) CA2421229A1 (en)
DE (1) DE60140681D1 (en)
DK (1) DK1315518T3 (en)
ES (1) ES2337653T3 (en)
GB (1) GB0021757D0 (en)
IL (1) IL154727A0 (en)
PT (1) PT1315518E (en)
WO (1) WO2002020045A2 (en)
ZA (1) ZA200301759B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2399614C2 (en) * 2004-09-21 2010-09-20 Астеллас Фарма Инк. Amino alcohol derivatives
EP2066341B1 (en) 2006-09-01 2015-07-15 CSL Limited Method of eliciting or inducing an immune response
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
SG185294A1 (en) 2007-10-12 2012-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
EA201391553A1 (en) * 2011-04-20 2014-03-31 Майко Байо, Инк. COMPOSITION AND METHOD OF STRENGTHENING IMMUNE RESPONSE

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785404T2 (en) * 1986-08-18 1993-07-29 British Tech Group Vaccines.
US5776724A (en) * 1988-10-24 1998-07-07 Yale University Chaperonin-mediated protein folding
JPH03204820A (en) * 1989-10-12 1991-09-06 Nippon Saibai Suisan Kk Preventive vaccine for bacterial disease of prawn and production thereof
JPH08509873A (en) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール Immune composition against Helicobacter infection, polypeptide used in the composition and nucleic acid sequence encoding the polypeptide
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH0748398A (en) * 1993-08-03 1995-02-21 Nippon Oil Co Ltd Method for regenerating denatured protein and regenerating agent for denatured protein
US6872542B1 (en) * 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
JPH11507214A (en) * 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Heat shock protein members of streptococci belonging to the HSP70 family
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
NZ322398A (en) * 1995-11-30 2000-02-28 Pig Res & Dev Corp Vaccine compositions comprising non-pathogenic form of Lawsonia intracellularis, nucleic acid sequences thereof and treatment of intestinal disease
EP0950061A4 (en) * 1996-09-20 2000-04-12 Univ New Mexico Heat shock protein complexes
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6500434B1 (en) * 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
CA2335487A1 (en) * 1998-06-19 1999-12-23 Merieux Oravax Lt and ct in parenteral immunization methods against helicobacter infection
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
WO2000050073A2 (en) * 1999-02-22 2000-08-31 University Of British Columbia Caulobacter lps immunoadjuvant
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
AU5708601A (en) * 2000-04-17 2001-10-30 James E Rothman Javelinization of protein antigens to heat shock proteins
CN1107681C (en) * 2000-08-11 2003-05-07 中国科学院微生物研究所 Compound of polypeptide as antigen of hepatitis B virus and heat shock protein and its application
US6932985B2 (en) * 2000-10-10 2005-08-23 Auburn University Azide method and composition for controlling deleterious organisms
WO2002059156A2 (en) * 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
CA2476556A1 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US8088569B2 (en) * 2002-03-01 2012-01-03 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
AU2003301296A1 (en) * 2002-05-02 2004-05-04 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines

Also Published As

Publication number Publication date
CA2421229A1 (en) 2002-03-14
ATE450270T1 (en) 2009-12-15
EP1315518A2 (en) 2003-06-04
DK1315518T3 (en) 2010-04-19
DE60140681D1 (en) 2010-01-14
IL154727A0 (en) 2003-10-31
WO2002020045A3 (en) 2002-10-31
US20050232946A1 (en) 2005-10-20
ZA200301759B (en) 2004-06-22
CN1452495A (en) 2003-10-29
GB0021757D0 (en) 2000-10-18
ES2337653T3 (en) 2010-04-28
PT1315518E (en) 2010-03-05
JP2004508339A (en) 2004-03-18
WO2002020045A2 (en) 2002-03-14
EP1315518B1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
ATE219948T1 (en) RECOMBINANT VACCINES THAT CONTAIN IMMUNOGENE ATTENUATE RPOS-POSITIVE PHENTOTYPE BACTERIA
WO2004030608A3 (en) Nanoemulsion vaccines
AU2001284261A1 (en) Vaccine against microbial pathogens
DE69322092T2 (en) NEW BACTERIAL VACCINES USING VACCINE STRAINS FROM PATHOGENIC BACTERIA
DE602004028029D1 (en) Rwendung
ATE315090T1 (en) VACCINE PRODUCTION OF THE BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
NO20004781D0 (en) Attenuated bacteria useful in vaccines
WO2001063278A3 (en) Antigenic fragments associated with stress-induced proteins and their use as vaccines
NO20062469L (en) Streptococcus phocae vaccine
DE60218327D1 (en) INACTIVATED IMMUNOGENIC BACTERIAL ALL-CELL COMPOSITIONS
EP1361794A4 (en) Pro-apoptotic bacterial vaccines to enhance cellular immune responses
DK1334197T3 (en) Yeast-derived vaccine against IPNV
CY1105947T1 (en) MYCOPLASMA HYOPNEUMONIAE MHP3 GENE NUCLEIC ACIDS AND PROTEINS AND USES THEREOF
WO2005012538A3 (en) Accelerated vaccination
GB9919734D0 (en) Vaccines from infectious agents
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2004073603A3 (en) Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
WO2002067982A3 (en) Mycobacterial vaccines
AU1853995A (en) Vaccine compositions
IL148154A0 (en) Vaccine against intra-cellular pathogens
AP2003002944A0 (en) Method to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production.
ATE341613T1 (en) FLUORDESOXYURIDINE RESISTANT STREPTOCOCCUS GORDONII STRAINS
CU23358B7 (en) VACCINE THAT INCLUDES A GARRAPATA CEMENT PROTEIN